Towards a simple
journey in UC

JYSELECA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

A simple choice. JYSELECA is a convenient, efficacious and rapid treatment that is well tolerated1,2

Rapid symptomatic improvement (post-hoc analysis):1,2 

  • Day 6 improvement in Biologic-Naïve patients
  • Day 3 improvement in Biologic-Experienced patients
  • Week 2 partial Mayo Clinic Score remission

Sustained clinical remission (at both Weeks 10 and 58), histologic remission, and ≥6-month corticosteroid-free clinical remission3

JAK1-preferential inhibitor that has been well tolerated in clinical trials3

Convenient oral formulation, once-daily tablet3

JYSELECA can help improve the quality of life for your patients with UC4

References: 1. Vermeire S, Oortwijn A, Feagan BG, et al. DDW 2021. FR537. 2. Danese S, Hibi T, Ritter TE, et al. ECCO 2021. OP37. 3. Feagan BG, Danese S, Loftus EV Jr, et al. Lancet 2021;397:2372–2384. 4. Sandborn WJ, Peyrin-Biroulet L, Danese S, et al. UEGW 2021. P0457.